ZA201706923B - T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car) - Google Patents

T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car)

Info

Publication number
ZA201706923B
ZA201706923B ZA2017/06923A ZA201706923A ZA201706923B ZA 201706923 B ZA201706923 B ZA 201706923B ZA 2017/06923 A ZA2017/06923 A ZA 2017/06923A ZA 201706923 A ZA201706923 A ZA 201706923A ZA 201706923 B ZA201706923 B ZA 201706923B
Authority
ZA
South Africa
Prior art keywords
cell
receptor
tcr
expresses
delta
Prior art date
Application number
ZA2017/06923A
Other languages
English (en)
Inventor
Anderson John
Fisher Jonathan
PULÉ Martin
Gustafsson Kenth
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of ZA201706923B publication Critical patent/ZA201706923B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2017/06923A 2015-04-30 2017-10-12 T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car) ZA201706923B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1507368.7A GB201507368D0 (en) 2015-04-30 2015-04-30 Cell
PCT/GB2016/051235 WO2016174461A1 (en) 2015-04-30 2016-04-29 T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car)

Publications (1)

Publication Number Publication Date
ZA201706923B true ZA201706923B (en) 2022-02-23

Family

ID=53488907

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/06923A ZA201706923B (en) 2015-04-30 2017-10-12 T cell which expresses a gamma-delta t cell receptor (tcr) and a chimeric antigen receptor (car)

Country Status (16)

Country Link
US (2) US20180125890A1 (https=)
EP (1) EP3288567B1 (https=)
JP (1) JP6986449B2 (https=)
KR (1) KR20180020140A (https=)
CN (1) CN107771215A (https=)
AU (1) AU2016255611B2 (https=)
BR (1) BR112017023409A2 (https=)
CA (1) CA2982532C (https=)
EA (1) EA201792042A1 (https=)
ES (1) ES3018558T3 (https=)
GB (1) GB201507368D0 (https=)
HK (1) HK1252235A1 (https=)
IL (1) IL255186B (https=)
SG (1) SG11201708402UA (https=)
WO (1) WO2016174461A1 (https=)
ZA (1) ZA201706923B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
DK3143134T3 (da) 2014-05-15 2021-01-04 Nat Univ Singapore Modificerede, naturlige dræberceller og anvendelser deraf
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CA3057838A1 (en) * 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
BR112019019917A2 (pt) 2017-03-27 2020-04-22 Nat Univ Singapore receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
US20210130775A1 (en) * 2017-08-02 2021-05-06 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
WO2019067249A1 (en) * 2017-09-27 2019-04-04 Ohio State Innovation Foundation CAR-NK CELL THERAPY AND TISSUE FACTOR TARGETING T-CARD
GB201715918D0 (en) * 2017-09-29 2017-11-15 Tc Biopharm Ltd Modified CAR-T
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
EP3749685A4 (en) 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
WO2019192526A1 (zh) * 2018-04-04 2019-10-10 达仁生物科技有限公司 嵌合抗原受体和其治疗癌症的方法
JP7436383B2 (ja) * 2018-04-18 2024-02-21 ユーシーエル ビジネス リミテッド 操作された調節性ｔ細胞
CN108588023B (zh) 2018-05-09 2020-02-14 河北森朗生物科技有限公司 一种生产嵌合抗原受体修饰的γδT细胞的方法
CN110577932A (zh) * 2018-06-07 2019-12-17 亘喜生物科技（上海）有限公司 一种脐带血来源的嵌合抗原受体t细胞
SG11202008731XA (en) * 2018-06-19 2020-10-29 Nanjing Legend Biotech Co Ltd Engineered cells and uses thereof
CA3102641A1 (en) * 2018-06-22 2019-12-26 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
EP3831936A4 (en) 2018-07-31 2022-04-13 Thyas Co. Ltd. METHOD FOR PRODUCING A REGENERATED T LYMPHOCYTE POPULATION USING IPS CELLS
US12156888B2 (en) 2018-08-07 2024-12-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T-cells for the treatment of bone metastatic cancer
US12569507B2 (en) 2018-08-07 2026-03-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T-cells for the treatment of bone metastatic cancer
CN112567025B (zh) * 2018-08-10 2025-01-17 国立大学法人京都大学 Cd3阳性细胞的制造方法
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
AU2019344300A1 (en) * 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
SG11202103234RA (en) * 2018-10-01 2021-04-29 Adicet Bio Inc COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS
US20210388100A1 (en) * 2018-10-01 2021-12-16 Adicet Bio, Inc. Compositions and methods regarding engineered and non-engineered gamma delta t-cells for treatment of hematological tumors
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
WO2020156335A1 (zh) 2019-01-29 2020-08-06 上海交通大学 一种嵌合抗原受体及其应用
WO2020172555A1 (en) * 2019-02-21 2020-08-27 Regents Of The University Of Minnesota Genetically modified gamma delta t cells and methods of making and using
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
SG11202109051PA (en) * 2019-04-12 2021-10-28 Phanes Therapeutics Inc Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof
WO2020216238A1 (en) * 2019-04-22 2020-10-29 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
CN113939302A (zh) 2019-06-14 2022-01-14 赛雅思株式会社 医药组合物
US20220259281A1 (en) * 2019-06-21 2022-08-18 Shattuck Labs, Inc. Chimeric protein expressing t-cells
GB201909283D0 (en) * 2019-06-27 2019-08-14 Cancer Research Tech Ltd Fusion proteins with enzyme activity
CN110981972B (zh) * 2019-12-25 2022-09-30 华夏源（上海）细胞基因工程股份有限公司 一种分泌双特异性抗体的嵌合抗原受体及其表达载体和应用
CN115485369A (zh) * 2020-03-03 2022-12-16 詹森生物科技公司 γδT细胞及其用途
US20230203125A1 (en) 2020-05-22 2023-06-29 Chongqing Precision Biotech Co., Ltd. Fusion protein for reversing tumor microenvironment and use thereof
EP4182338A1 (en) 2020-07-17 2023-05-24 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2022266192A1 (en) 2021-06-16 2022-12-22 Instil Bio, Inc. Receptors providing targeted costimulation for adoptive cell therapy
EP4370213A4 (en) 2021-07-16 2025-06-04 Instil Bio (Uk) Limited Chimeric molecules for targeted costimulation for adoptive cell therapy
CN113528455A (zh) * 2021-07-19 2021-10-22 广州百暨基因科技有限公司 表达嵌合抗原受体的γδT细胞
US20240408139A1 (en) * 2021-10-06 2024-12-12 Dana-Farber Cancer Institute, Inc. Engineered cytokine receptors for tunable adoptive cell therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1147186A4 (en) 1999-01-28 2002-05-15 Palmetto Health Alliance D B A In vitro activated gamma delta lymphocytes
ES2336302T3 (es) 2000-04-03 2010-04-12 Therapure Biopharma Inc. Produccion de celulas ttcr gamma delta.
DE60115069T2 (de) 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
WO2006006720A1 (ja) 2004-07-13 2006-01-19 Medinet., Co.Ltd γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
DE602005022728D1 (de) 2004-08-19 2010-09-16 Univ Cardiff Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie
JPWO2008152822A1 (ja) 2007-06-15 2010-08-26 株式会社メディネット 医薬
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013033626A2 (en) * 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
CA2861491C (en) * 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
CN113005091A (zh) 2013-02-06 2021-06-22 细胞基因公司 具有改进特异性的修饰的t淋巴细胞
JP6647868B2 (ja) * 2013-02-20 2020-02-14 ノバルティス アーゲー ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3925618A1 (en) * 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
EP3060059A4 (en) 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
MX373687B (es) * 2013-11-21 2020-07-07 Ucl Business Ltd Célula natural (nk)
KR102375998B1 (ko) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 항원 수용체 및 제조방법
GB201403972D0 (en) * 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
CA2945388A1 (en) * 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
CN107075480A (zh) 2014-07-09 2017-08-18 Tc生物制药有限公司 γδT细胞及其用途
IL297773B2 (en) 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
CN105158466B (zh) 2015-05-05 2017-12-22 中国科学院广州生物医药与健康研究院 一种检测抗cd19的嵌合抗原受体t细胞对白血病细胞抑制作用的方法

Also Published As

Publication number Publication date
AU2016255611A1 (en) 2017-11-02
AU2016255611B2 (en) 2021-08-05
US20220211756A1 (en) 2022-07-07
BR112017023409A2 (en) 2018-07-24
EP3288567A1 (en) 2018-03-07
CA2982532C (en) 2023-10-03
IL255186B (en) 2022-02-01
CN107771215A (zh) 2018-03-06
KR20180020140A (ko) 2018-02-27
SG11201708402UA (en) 2017-11-29
IL255186A0 (en) 2017-12-31
CA2982532A1 (en) 2016-11-03
EA201792042A1 (ru) 2018-03-30
US12331316B2 (en) 2025-06-17
HK1252235A1 (zh) 2019-05-24
US20180125890A1 (en) 2018-05-10
EP3288567B1 (en) 2025-03-19
JP2018514204A (ja) 2018-06-07
GB201507368D0 (en) 2015-06-17
ES3018558T3 (es) 2025-05-16
WO2016174461A1 (en) 2016-11-03
JP6986449B2 (ja) 2021-12-22

Similar Documents

Publication Publication Date Title
IL255186B (en) T cell that expresses T cell gamma delta receptor (tcr) and chimeric antigen receptor (car)
IL292508B1 (en) A cell that simultaneously expresses a chimeric antigen receptor (car) of 19cd and 22cd
IL261525A (en) Cells expressing multiple chimeric receptor-antigen molecules (car) and their use
IL254254A0 (en) chimeric antigen receptor
DK3265490T3 (en) Chimeric antigen receptor (car) comprising a cd19-binding domain
SG10201913245UA (en) Antibody/t-cell receptor chimeric constructs and uses thereof
EP3286225A4 (en) Cd5 chimeric antigen receptor for adoptive t cell therapy
GB201607968D0 (en) Chimeric antigen receptor
IL256058B (en) Lym-1 and lym-2 targeted car cell immunotherapy
SG11201606790XA (en) Chimeric antigen receptor
GB201610512D0 (en) Chimeric antigen receptor
IL257295B (en) Chimeric antigen receptors, and T cells in which expression of a chimeric antigen receptor is measured
ZA201906321B (en) Chimeric antigen receptor
PL3529267T3 (pl) Receptor komórek t
IL266950B1 (en) γδ t cells expressing a chimeric antigen receptor for use in immunotherapy
GB201709508D0 (en) Chimeric antigen receptor
GB201810451D0 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201519900D0 (en) Chimeric antigen receptor
GB201721421D0 (en) Chimeric antigen receptor
HK40022368A (en) A cell comprising a chimeric antigen receptor (car)
GB201721831D0 (en) T cell antigen receptor chimera
AU2016902764A0 (en) Chimeric antigen receptor modified T cells
GB201612844D0 (en) Chimeric antigen receptor
GB201612533D0 (en) Chimeric antigen receptor
GB201604387D0 (en) Chimeric antigen receptor